Market Overview:
The global tyrosine protein kinase receptor TYRO3 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of cancer, rising awareness about cancer diagnosis and treatment options, and technological advancements in cancer diagnosis and treatment. The TYRO3 market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into RXDX-106, ELB-031, Q-701, and others. On the basis of application, the market is segmented into bladder cancer breast cancer metastatic colorectal cancer ovariancancer others). The North America region dominatesthe global TYRO3market due to early adoptionof new technologiesand better reimbursement scenario for advanced therapies in this region.
Product Definition:
A tyrosine protein kinase receptor, also known as TYRO3, is a type of receptor that mediates the effects of tyrosine kinases. Tyrosine protein kinases are a family of enzymes that catalyze the transfer of phosphate groups from ATP to specific amino acids in proteins. TYRO3 is important for the development and function of immune cells, and mutations in this gene have been associated with various autoimmune diseases.
RXDX-106:
RXDX-106 is a novel small molecule inhibitor for Tyrosine Protein Kinase Receptor (TYRO3). It has shown potent and selective inhibition of the receptor in vitro & in vivo. The compound has been developed by a global pharmaceutical company, but was later acquired by another drug development company after positive results were observed for the compound.
ELB-031:
ELB-031 is a novel small molecule inhibitor for Tyrosine Protein Kinase Receptor TYRO3 with IC50 of 0.8 uM. It has been discovered by the Eli Lilly and Company and is currently under clinical trial phase in the U.S., Canada, Europe, China, Australia & Japan for treatment of Non-Alcoholic Steatohepatitis (NASH) which is expected to be launched in 2019.
Application Insights:
The breast cancer segment dominated the global tyrosine protein kinase receptor TYRO3 market in terms of revenue in 2017. This is due to the high prevalence of breast cancer and increasing number of drug candidates for its treatment. For instance, cabozantinib (ZINPLAVA) is a pan-HER2 inhibitor that targets both human epidermal growth factor receptor 2 (HER2) and human ErbB1 receptors with higher affinity towards HER2 than ErbB1.
Owing to these factors, bladder cancer is expected to be one of the fastest-growing segments during the forecast period. Bladder tumorigenesis has been extensively studied over recent years; however, there are few data regarding molecular mechanisms involved in its development and progression which can be used as a basis for developing novel therapeutic strategies against this disease.
Regional Analysis:
North America accounted for the largest share of revenue in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some factors contributing to its large share. In addition, the high prevalence of cancer is also expected to drive regional growth over the forecast period. For instance, as per Breastcancer.org website in U.S., around 1 out of 3 women will be diagnosed with breast cancer over their lifetime and about 40% will die from it within 10 years after diagnosis (2017).
Asia Pacific market was estimated at USD X million in 2017.
Growth Factors:
- Increasing prevalence of cancer and other chronic diseases: The global incidence of cancer is increasing at an alarming rate. According to the World Health Organization, the number of new cases is expected to rise from 14 million in 2012 to 24 million by 2040. This will create a large pool of patients who will require treatment with tyrosine protein kinase receptor TYRO3 inhibitors, driving the market growth.
- Growing demand for targeted therapies: Cancer is becoming increasingly resistant to traditional chemotherapy and radiation therapy regimens. As a result, there is growing demand for targeted therapies that can specifically block the action of oncogenic proteins involved in tumor growth and progression. Tyrosine protein kinase receptor TYRO3 inhibitors are one such class of drugs that show great promise as targeted therapies for various cancers.
- Technological advancements in tyrosine protein kinase receptor TYRO3 research: The field of tyrosine protein kinase receptor TYRO3 research is rapidly evolving with new technological advancements being made every day. This has led to the development of better diagnostic tools and novel therapeutics which are likely to fuel market growth over the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Tyrosine Protein Kinase Receptor TYRO3 Market Research Report
By Type
RXDX-106, ELB-031, Q-701, Others
By Application
Bladder Cancer, Breast Cancer, Metastatic Colorectal Cancer, Ovarian Cancer, Others
By Companies
Celldex Therapeutics Inc, Elsalys Biotech SAS, Ignyta Inc, Qurient Co Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
204
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Tyrosine Protein Kinase Receptor TYRO3 Market Report Segments:
The global Tyrosine Protein Kinase Receptor TYRO3 market is segmented on the basis of:
Types
RXDX-106, ELB-031, Q-701, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Bladder Cancer, Breast Cancer, Metastatic Colorectal Cancer, Ovarian Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celldex Therapeutics Inc
- Elsalys Biotech SAS
- Ignyta Inc
- Qurient Co Ltd
Highlights of The Tyrosine Protein Kinase Receptor TYRO3 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- RXDX-106
- ELB-031
- Q-701
- Others
- By Application:
- Bladder Cancer
- Breast Cancer
- Metastatic Colorectal Cancer
- Ovarian Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tyrosine Protein Kinase Receptor TYRO3 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tyrosine Protein Kinase Receptor TYRO3 is a protein that in humans is encoded by the TYRO3 gene. The TYRO3 gene encodes a receptor for the tyrosine kinases, which are enzymes that catalyze the transfer of phosphate groups from ATP to tyrosines in proteins. This receptor plays an important role in cell growth and differentiation.
Some of the major players in the tyrosine protein kinase receptor tyro3 market are Celldex Therapeutics Inc, Elsalys Biotech SAS, Ignyta Inc, Qurient Co Ltd.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tyrosine Protein Kinase Receptor TYRO3 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tyrosine Protein Kinase Receptor TYRO3 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tyrosine Protein Kinase Receptor TYRO3 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tyrosine Protein Kinase Receptor TYRO3 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tyrosine Protein Kinase Receptor TYRO3 Market Size & Forecast, 2020-2028
4.5.1 Tyrosine Protein Kinase Receptor TYRO3 Market Size and Y-o-Y Growth
4.5.2 Tyrosine Protein Kinase Receptor TYRO3 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 RXDX-106
5.2.2 ELB-031
5.2.3 Q-701
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Bladder Cancer
6.2.2 Breast Cancer
6.2.3 Metastatic Colorectal Cancer
6.2.4 Ovarian Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tyrosine Protein Kinase Receptor TYRO3 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tyrosine Protein Kinase Receptor TYRO3 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 RXDX-106
9.6.2 ELB-031
9.6.3 Q-701
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Bladder Cancer
9.10.2 Breast Cancer
9.10.3 Metastatic Colorectal Cancer
9.10.4 Ovarian Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 RXDX-106
10.6.2 ELB-031
10.6.3 Q-701
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Bladder Cancer
10.10.2 Breast Cancer
10.10.3 Metastatic Colorectal Cancer
10.10.4 Ovarian Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 RXDX-106
11.6.2 ELB-031
11.6.3 Q-701
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Bladder Cancer
11.10.2 Breast Cancer
11.10.3 Metastatic Colorectal Cancer
11.10.4 Ovarian Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 RXDX-106
12.6.2 ELB-031
12.6.3 Q-701
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Bladder Cancer
12.10.2 Breast Cancer
12.10.3 Metastatic Colorectal Cancer
12.10.4 Ovarian Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 RXDX-106
13.6.2 ELB-031
13.6.3 Q-701
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Bladder Cancer
13.10.2 Breast Cancer
13.10.3 Metastatic Colorectal Cancer
13.10.4 Ovarian Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tyrosine Protein Kinase Receptor TYRO3 Market: Competitive Dashboard
14.2 Global Tyrosine Protein Kinase Receptor TYRO3 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Celldex Therapeutics Inc
14.3.2 Elsalys Biotech SAS
14.3.3 Ignyta Inc
14.3.4 Qurient Co Ltd
